MakiDGSchunaAA. A study of antimicrobial misuse in a university hospital. Am J Med Sci1978; 275: 271–82.
2.
RobertsAWViscontiJV. The rational and irrational use of systemic antimicrobial drugs. Am J Hosp Pharm1972; 29: 828–33.
3.
KurunCMTupasiTCraigWA. Use of antibiotics: A brief exposition of the problem and some tentative solutions. Ann Intern Med1973; 79: 555.
4.
CastleMWilfertCMCateTR, Antibiotic use at Duke University Medical Center. JAMA1977; 237: 2819.
5.
KuninCM. Problems in antibiotic usage. In: MandellGLDouglasRGBennettJE, eds. Principles and practice of infectious diseases. New York: John Wiley & Sons, 1985: 301–7.
6.
PorterJJickH. Drug-related deaths among medical inpatients. JAMA1977; 237: 879–81.
7.
PowersDA. Antimicrobial surveillance in a VAMC teaching hospital—resulting cost avoidance. Drug Intell Clin Pharm1986; 20: 803–5.
8.
KnappDEKnappDASpeedleMK, Relationship of inappropriate drug prescribing to increased length of hospital stay. Am J Hosp Pharm1979; 36: 1334–7.
9.
GreenJWWenzelRP. Postoperative wound infection: A controlled study of the increased duration of hospital stay and direct cost of hospitalization. Ann Surg1977; 185: 264–8.
10.
LevySB. Microbial resistance to antibiotics: An evolving and persistent problem. Lancet1982; 2: 83–8.
11.
SoumeraiSBAvornJ. Efficacy and cost-containment in hospital pharmacotherapy: State of the art and future directions. Milbank Memorial Fund Q Health and Society1984; 62: 447–74.
12.
SchroederSAMyersLPMcPheeSJ, The failure of physician education as a cost containment strategy. JAMA1984; 252: 225–30.
13.
AbramowitzPWNoldEGHatfieldSM. Use of clinical pharmacists to reduce cefamandole, cefoxitin, and ticarcillin costs. Am J Hosp Pharm1982; 39: 1176–80.
14.
BrittonHLSchwinghammerTRomanoMJ. Cost containment through restriction of cephalosporins. Am J Hosp Pharm1981; 38: 1897–900.
15.
CovinskyJOHamburgerSCKellyKL. The impact of the do-cent clinical pharmacist on treatment of streptococcal pneumonia. Drug Intell Clin Pharm1982; 16: 587–91.
16.
DurbinWALapidasBGoldmannDA. Improved antibiotic usage following introduction of a novel prescription system. JAMA1981; 246: 1796–800.
17.
JewessonPJHoRJangQ, Auditing antibiotic use in a teaching hospital: Focus on cefoxitin. Can Med Assoc J1983: 128: 1075–8.
SuzukiNTPelhamLD. Cost benefit of pharmacist concurrent monitoring of cefazolin prescribing. Am J Hosp Pharm1983; 40: 1187–91.
20.
McGowanJEFinlandM. Usage of antibiotics in a general hospital: Effect of requiring justification. J Infect Dis1974; 130: 165–8.
21.
ReccoRAGladstoneJLFriedmanSA, Antibiotic control in a municipal hospital. JAMA1979; 241: 2283–6.
22.
HeplerCDClyneKEDontaST. Rationales expressed by empiric antibiotic prescribers. Am J Hosp Pharm1982; 39: 1647–55.
23.
Study commission on pharmacy. Pharmacists for the future: The report of the study commission on pharmacy. Ann Arbor, MI: Health Administration, 1975.
24.
AbramowitzPWNoldEGHatfieldSM. Use of clinical pharmacists to reduce cefamandole, cefoxitin, and ticarcillin costs. Am J Hosp Pharm1982; 39: 1176–80.
25.
GuernseyBGBerinaLFLazarusMC, Cost containment through therapeutic substitution of aminoglycosides. Hosp Pharm1985; 20: 82–95.
26.
StrattonTPPlachetkaJRGainesJA. Cost savings from hetastarch use in place of albumin on a cardiothoracic surgery service. Hosp Formul1984; 19: 571–6.
27.
TownsendRJBakerRP. Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Drug Intell Clin Pharm1987; 21: 279–81.
28.
SavitskyMEKirkingDMCornishLA, Costs associated with the inappropriate route of administration of parenteral histamine2-receptor antagonists. Drug Intell Clin Pharm1987; 21: 885–9.
29.
BootmanJLWertheimerAIZaskeD, Individualizing gentamicin dosage regimens in bum patients with gram negative septicemia: Cost-benefit analysis. J Pharm Sci1979; 68: 267–72.
30.
GoffDThorntonJP. Pharmacy-laboratory interactions: A unique method to control antibiotic cost. Hosp Pharm1989; 24: 26–32.